
Repligen Corporation
NASDAQ•RGEN
CEO: Mr. Anthony J. Hunt
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1986-04-29
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Contact Information
Building 1, Suite 100 41 Seyon Street, Waltham, MA, 02453, United States
781-250-0111
Market Cap
$8.58B
P/E (TTM)
4927.7
76.6
Dividend Yield
--
52W High
$182.52
52W Low
$102.97
52W Range
4.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$188.81M+21.91%
4-Quarter Trend
EPS
$0.27-15.63%
4-Quarter Trend
FCF
$43.90M+4.08%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Strong Revenue Growth Nine Months Total revenue reached $540.3M USD for nine months, marking a 15.7% increase compared to $466.9M USD prior year.
Net Income Substantially Higher Nine months net income was $35.6M USD, a substantial increase from $8.4M USD reported in the same period last year.
Goodwill Increased Post-Acquisition Total goodwill grew to $1.113B USD, driven by the $50.1M provisional goodwill recognized from the 908 Devices acquisition.
R&D Spending Rises 30.2% Research and development expenses increased to $41.1M USD for nine months, reflecting integration costs from recent business acquisitions.
Risk Factors
Unremediated Internal Control Weaknesses Material weaknesses in IT general controls and revenue recognition evaluation remain unremediated as of September 30, 2025.
Contingent Consideration Valuation Risk Contingent consideration earnouts rely on Level 3 unobservable inputs, subject to refinement and potential future obligation changes.
Future Capital Requirements Uncertainty Future capital needs may require seeking additional financing, potentially leading to shareholder dilution via equity or debt issuance.
Foreign Currency Exchange Exposure Global revenue subjects the company to non-U.S. exchange exposure, where volatile rates could impact reported gross profit margins.
Outlook
Focus on 908 Devices Integration Integration of the 908 Devices PAT Portfolio is key to maximizing platform value and optimizing customer development processes.
Finalizing Purchase Price Allocations Purchase accounting for 908 Devices and Tantti acquisitions remains provisional, expected to finalize before Q1 2026 reporting.
Monitoring New Tax Legislation Management is evaluating the impact of the recently enacted OBBBA tax legislation, effective through 2027, on financial statements.
Peer Comparison
Revenue (TTM)
BDX$21.84B
ISRG$9.61B
RMD$5.26B
Gross Margin (Latest Quarter)
ISRG66.4%
COO65.3%
RMD61.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ISRG | $196.30B | 71.3 | 16.1% | 0.0% |
| BDX | $55.33B | 33.0 | 6.6% | 34.7% |
| RMD | $35.83B | 24.9 | 25.1% | 10.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+4.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $188.81M+21.9%|EPS: $0.27-15.6%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 7, 2025|Revenue: $182.37M+18.4%|EPS: $0.26+337.7%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 29, 2025|Revenue: $169.17M+11.8%|EPS: $0.10+150.0%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 14, 2025|Revenue: $634.44M+0.3%|EPS: $-0.46-171.9%MissForm 10-Q/A - Q1 2023
Period End: Mar 31, 2023|Filed: Nov 18, 2024|Revenue: $182.66M-11.5%|EPS: $0.52-35.8%MissForm 10-Q/A - Q2 2023
Period End: Jun 30, 2023|Filed: Nov 18, 2024|Revenue: $159.17M-23.3%|EPS: $0.36-60.0%MissForm 10-Q/A - Q2 2024
Period End: Jun 30, 2024|Filed: Nov 18, 2024|Revenue: $154.07M-3.2%|EPS: $0.06-83.5%MissForm 10-Q/A - Q3 2023
Period End: Sep 30, 2023|Filed: Nov 18, 2024|Revenue: $141.19M-29.7%|EPS: $0.33-54.8%Beat